Autopsy report · NCT03670901
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Cause of deathFunding or business
“The development was stopped due to company's strategy consideration”
Life of this trial
- Registered 2 months before it started.
- Ran for about 4 months before it stopped.
- 8 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- JHL Biotech, Inc.
- Sponsor type
- Industry
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- JHL1101; MabThera
- Participants
- 8
- Sites
- 1
- Countries
- China
Trials that died the same way
- IBI397 or Combination Therapies in Patients With Advanced Malignancies
“Due to the company's development strategy adjustment” - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
“Product development halted for business reasons.” - Study of NIB101 in Participants With Advanced Solid Tumors
“due to the reconsideration of development strategy” - The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
“strategy terminates development, the decision is not due to any safety-related issues” - A Study to Test if TEV-53275 is Effective in Relieving Asthma
“Stopped for strategic reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.